Corvus Pharmaceuticals Eyes Expansion Of Blood Cancer Therapy but Resource Limitations Pose Challenge: Oppenheimer

Oppenheimer has initiated coverage on Corvus Pharmaceuticals Inc (NASDAQ:CRVS) with an Outperform rating and a price target of $7.00.

Analysts Jeff Jones and Kyle Yang see relapsed/refractory peripheral T-cell lymphoma as a gateway indication for soquelitinib, with regulatory guidance on the pivotal plan in r/r PTCL anticipated this quarter, following a scheduled FDA meeting.